Intrathecal Drug Delivery for Chronic Pain Syndromes: A Review of Considerations in Practice Management.

BACKGROUND Chronic pain syndromes are poorly understood and challenging to treat. However, intrathecal drug delivery systems (IDDS) have been shown to have good efficacy in treating various pain subtypes and patient populations. The success of IDDS interventions is largely dependent on consideration of and adherence to varying practice patterns. OBJECTIVES We aimed to review and report on the evidence basis for various considerations in IDDS practice management including: (1) patient selection and periprocedural criteria, (2) efficacy of IDDS for various conditions, (3) intrathecal medications, (4) drug delivery systems, (5) trial and implantation, (6) complications and adverse events, and (7) chronic follow-up. STUDY DESIGN We conducted an evidence-based narrative review. METHODS PubMed, Medline, Cochrane Library, prior systematic reviews, and reference lists were screened by 2 separate authors for all randomized trials, meta-analyses, and observational studies relevant to each of the aforementioned management principles and were considered for study inclusion. RESULTS All high-level evidence studies that explored the various facets for IDDS practice management were included for review. LIMITATIONS Despite existing evidence basis for practice considerations, current practice patterns are highly practitioner dependent. More and continued high-level evidence is necessary to support, affirm, and dictate principles in practice considerations. CONCLUSIONS Incorporation of the principles found in this evidence-based narrative, which is comprised of the highest level of evidence supportive of various facets of IDDS practice management, is essential to optimize outcomes, treatment efficacy, and safety profiles.

[1]  F. Hans,et al.  Long‐term Outcome and Adverse Events of Intrathecal Opioid Therapy for Nonmalignant Pain Syndrome , 2020, Pain practice : the official journal of World Institute of Pain.

[2]  F. Öner,et al.  The efficacy of intrawound vancomycin powder and povidone-iodine irrigation to prevent Surgical Site Infections in complex instrumented spine surgery. , 2019, The spine journal : official journal of the North American Spine Society.

[3]  B. D. Ward,et al.  Care Bundle Approach to Minimizing Infection Rates after Neurosurgical Implants for Neuromodulation: A Single-Surgeon Experience. , 2019, World neurosurgery.

[4]  T. Deer,et al.  Intrathecal drug delivery for pain management: recent advances and future developments , 2019, Expert opinion on drug delivery.

[5]  V. Haughton,et al.  Subject-Specific Studies of CSF Bulk Flow Patterns in the Spinal Canal: Implications for the Dispersion of Solute Particles in Intrathecal Drug Delivery , 2019, American Journal of Neuroradiology.

[6]  P. Manganotti,et al.  The use ultrasound guided for refilling intrathecal baclofene pump in complicated clinical cases: A practical approach , 2018, Journal of Clinical Neuroscience.

[7]  Takashi Okamoto,et al.  Short-term results of intrathecal injection of low-dose bupivacaine in outpatients with chronic low back and lower extremity pain , 2018, European Spine Journal.

[8]  W. Poon,et al.  Blessing or burden? Long‐term maintenance, complications and clinical outcome of intrathecal baclofen pumps† , 2018, Surgical practice.

[9]  S. Nagel,et al.  Long-term Outcomes Using Intrathecal Drug Delivery Systems in Complex Regional Pain Syndrome , 2018, Pain medicine.

[10]  M. J. Hernández-Cádiz,et al.  Medical Device Related Pressure Injury in the Treatment of Chronic Pain: An Early Sign of Explantation in Suspected Infection. , 2018, Pain physician.

[11]  R. Mohanty,et al.  Psychiatric comorbidities among opioid-dependent patients attending department of psychiatry, regional institute of medical sciences hospital, Manipur , 2018, Indian Journal of Social Psychiatry.

[12]  M. Saulino,et al.  Effectiveness and Safety of Intrathecal Ziconotide: Interim Analysis of the Patient Registry of Intrathecal Ziconotide Management (PRIZM) , 2018, Pain Practice.

[13]  Jeffrey S. Raskin,et al.  A standardized protocol to reduce pediatric baclofen pump infections: a quality improvement initiative. , 2018, Journal of neurosurgery. Pediatrics.

[14]  T. Lamer,et al.  Bleeding Complications in Patients Undergoing Intrathecal Drug Delivery System Implantation , 2017, Pain medicine.

[15]  M. Lagerkranser Neuraxial blocks and spinal haematoma: Review of 166 case reports published 1994–2015. Part 1: Demographics and risk-factors , 2017, Scandinavian journal of pain.

[16]  M. Saulino,et al.  The Polyanalgesic Consensus Conference (PACC): Recommendations for Trialing of Intrathecal Drug Delivery Infusion Therapy , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[17]  M. Saulino,et al.  The Polyanalgesic Consensus Conference (PACC): Recommendations for Intrathecal Drug Delivery: Guidance for Improving Safety and Mitigating Risks , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[18]  M. Saulino,et al.  The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[19]  K. Slavin,et al.  The Neurostimulation Appropriateness Consensus Committee (NACC): Recommendations on Bleeding and Coagulation Management in Neurostimulation Devices , 2017, Neuromodulation : journal of the International Neuromodulation Society.

[20]  M. Choinière,et al.  Risk of Opioid Abuse and Biopsychosocial Characteristics Associated With This Risk Among Chronic Pain Patients Attending a Multidisciplinary Pain Treatment Facility , 2016, The Clinical journal of pain.

[21]  S. Parasa,et al.  Incidence, predictors and outcomes of hematoma after ICD implantation: An analysis of a nationwide database of 85,276 patients , 2016, Indian pacing and electrophysiology journal.

[22]  T. Lamer,et al.  Surgical Site Infections in Cancer Patients with Intrathecal Drug Delivery Devices , 2016, Pain medicine.

[23]  A. Burton,et al.  Intrathecal Therapy for Cancer-Related Pain , 2016, Pain medicine.

[24]  J. Healey,et al.  Clinically Significant Pocket Hematoma Increases Long-Term Risk of Device Infection: BRUISE CONTROL INFECTION Study. , 2016, Journal of the American College of Cardiology.

[25]  R. Bollo,et al.  Risk factors for baclofen pump infection in children: a multivariate analysis. , 2016, Journal of neurosurgery. Pediatrics.

[26]  S. Hayek,et al.  Intrathecal Hydromorphone and Bupivacaine Combination Therapy for Post-Laminectomy Syndrome Optimized with Patient-Activated Bolus Device. , 2015, Pain medicine.

[27]  S. Lam,et al.  Impact of antibiotic prophylaxis for intrathecal baclofen pump surgery in pediatric patients. , 2015, Neurosurgical focus.

[28]  J. Pilitsis,et al.  Predictors of Spinal Cord Stimulation Success , 2015, Neuromodulation : journal of the International Neuromodulation Society.

[29]  D. Turnbull,et al.  Psychological Factors as Outcome Predictors for Spinal Cord Stimulation , 2015, Neuromodulation : journal of the International Neuromodulation Society.

[30]  T. Deer,et al.  Intrathecal Pharmacology Update: Novel Dosing Strategy for Intrathecal Monotherapy Ziconotide on Efficacy and Sustainability , 2015, Neuromodulation : journal of the International Neuromodulation Society.

[31]  T. Deer,et al.  Intrathecal drug delivery for pain: a clinical guide and future directions. , 2015, Pain management.

[32]  J. Eisenach,et al.  Intrathecal clonidine and adenosine: effects on pain and sensory processing in patients with chronic regional pain syndrome , 2015, Pain.

[33]  A. Sharan,et al.  Efficacy of intraoperative vancomycin powder use in intrathecal baclofen pump implantation procedures: Single institutional series in a high risk population , 2014, Journal of Clinical Neuroscience.

[34]  C. Jourdan,et al.  Occurrence of adverse events in long-term intrathecal baclofen infusion: a 1-year follow-up study of 158 adults. , 2014, Archives of physical medicine and rehabilitation.

[35]  Robert Levy,et al.  Best Practices for Intrathecal Drug Delivery for Pain , 2014, Neuromodulation : journal of the International Neuromodulation Society.

[36]  D. Novy,et al.  The association of presurgery psychological symptoms with postsurgery pain among cancer patients receiving implantable devices for pain management , 2014, Supportive Care in Cancer.

[37]  F. Motta,et al.  Analysis of complications in 430 consecutive pediatric patients treated with intrathecal baclofen therapy: 14-year experience. , 2014, Journal of Neurosurgery: Pediatrics.

[38]  K. Freedland,et al.  Prescription Opioid Analgesics Increase the Risk of Depression , 2014, Journal of General Internal Medicine.

[39]  R. Coffey,et al.  Intrathecal Gabapentin to Treat Chronic Intractable Noncancer Pain , 2013, Anesthesiology.

[40]  E. Ross,et al.  Aberrant Intrathecal Pump Refill: Ultrasound-guided Aspiration of a Substantial Quantity of Subcutaneous Hydromorphone , 2013, Regional Anesthesia & Pain Medicine.

[41]  T. Yearwood,et al.  Intrathecal administration of Infumorph® vs compounded morphine for treatment of intractable pain using the Prometra® programmable pump. , 2013, Pain medicine.

[42]  Atul Verma,et al.  Pacemaker or defibrillator surgery without interruption of anticoagulation. , 2013, The New England journal of medicine.

[43]  R. Duarte,et al.  Hypogonadism and low bone mineral density in patients on long-term intrathecal opioid delivery therapy , 2013, BMJ Open.

[44]  T. Taira,et al.  Rate of Complications Among the Recipients of Intrathecal Baclofen Pump in Japan: A Multicenter Study , 2013, Neuromodulation : journal of the International Neuromodulation Society.

[45]  D. Koyyalagunta,et al.  Infectious complications related to intrathecal drug delivery system and spinal cord stimulator system implantations at a comprehensive cancer pain center. , 2013, Pain physician.

[46]  T. Renoir Selective Serotonin Reuptake Inhibitor Antidepressant Treatment Discontinuation Syndrome: A Review of the Clinical Evidence and the Possible Mechanisms Involved , 2013, Front. Pharmacol..

[47]  T. Deer,et al.  Long‐Term Follow‐Up of a Novel Implantable Programmable Infusion Pump , 2013, Neuromodulation : journal of the International Neuromodulation Society.

[48]  H. Putter,et al.  Efficacy of Intrathecal Baclofen on Different Pain Qualities in Complex Regional Pain Syndrome , 2013, Anesthesia and analgesia.

[49]  R. Gebhardt,et al.  SynchroMed II intrathecal pump memory errors due to repeated magnetic resonance imaging. , 2012, Pain physician.

[50]  J. Ketchum,et al.  Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. , 2012, Pain medicine.

[51]  M. Saulino,et al.  Polyanalgesic Consensus Conference—2012: Consensus on Diagnosis, Detection, and Treatment of Catheter‐Tip Granulomas (Inflammatory Masses) , 2012, Neuromodulation : journal of the International Neuromodulation Society.

[52]  R. Duarte,et al.  A predictive model for intrathecal opioid dose escalation for chronic non-cancer pain. , 2012, Pain physician.

[53]  D. Kim,et al.  A Meta-Analysis of Randomized Controlled Trials Appraising the Efficacy and Safety of Cilostazol after Coronary Artery Stent Implantation , 2012, Cardiology.

[54]  R. Duarte,et al.  Intrathecal granuloma formation as result of opioid delivery: Systematic literature review of case reports and analysis against a control group , 2012, Clinical Neurology and Neurosurgery.

[55]  M. Giglio,et al.  Intrathecal combination of ziconotide and morphine for refractory cancer pain: A rapidly acting and effective choice , 2012, PAIN.

[56]  C. Labos,et al.  Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction , 2011, Canadian Medical Association Journal.

[57]  N. Mekhail,et al.  SPINE SECTION Original Research Article Combination of Intrathecal Opioids with Bupivacaine Attenuates Opioid Dose Escalation in Chronic Noncancer Pain Patients , 2016 .

[58]  D. Monnin,et al.  Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol. , 2011, Pain physician.

[59]  E. Visser,et al.  Massive clonidine overdose during refill of an implanted drug delivery device for intrathecal analgesia: a review of inadvertent soft-tissue injection during implantable drug delivery device refills and its management. , 2011, Pain medicine.

[60]  J. Grider,et al.  Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain. , 2011, Pain physician.

[61]  O. Rémy-Néris,et al.  Bilateral Subdural Hematoma Following Implantation of Intrathecal Drug Delivery Device , 2011, Neuromodulation : journal of the International Neuromodulation Society.

[62]  R. Bennett,et al.  Central sensitivity syndromes: mounting pathophysiologic evidence to link fibromyalgia with other common chronic pain disorders. , 2011, Pain management nursing : official journal of the American Society of Pain Management Nurses.

[63]  J. Marinus,et al.  Neuropathic Pain Section Original Research Article the Lack of Efficacy of Different Infusion Rates of Intrathecal Baclofen in Complex Regional Pain Syndrome: a Randomized, Double-blind, Crossover Studyp Me_1065 459..465 , 2022 .

[64]  H. Weiner,et al.  Intrathecal baclofen therapy: complication avoidance and management , 2011, Child's Nervous System.

[65]  R. Jamison,et al.  Substance misuse treatment for high-risk chronic pain patients on opioid therapy: A randomized trial , 2010, PAIN.

[66]  C. Marco,et al.  A statewide prescription monitoring program affects emergency department prescribing behaviors. , 2010, Annals of emergency medicine.

[67]  D. Turk,et al.  Intrathecal opioid therapy for chronic nonmalignant pain: a retrospective cohort study with 3-year follow-up. , 2010, Pain medicine.

[68]  H. Usmani,et al.  Efficacy of intrathecal midazolam with or without epidural methylprednisolone for management of post-herpetic neuralgia involving lumbosacral dermatomes. , 2010, Pain physician.

[69]  Howard S. Smith,et al.  Consensus guidelines for the selection and implantation of patients with noncancer pain for intrathecal drug delivery. , 2010, Pain physician.

[70]  T. Deer,et al.  Accuracy and efficacy of intrathecal administration of morphine sulfate for treatment of intractable pain using the Prometra® Programmable Pump , 2010, Neuromodulation : journal of the International Neuromodulation Society.

[71]  M. Fredrikson,et al.  To continue or discontinue aspirin in the perioperative period: a randomized, controlled clinical trial. , 2010, British journal of anaesthesia.

[72]  J. Marinus,et al.  Intrathecal glycine for pain and dystonia in complex regional pain syndrome , 2009, PAIN.

[73]  L. Webster,et al.  Long-term intrathecal ziconotide for chronic pain: an open-label study. , 2009, Journal of pain and symptom management.

[74]  S. Hassenbusch,et al.  Practice choices and challenges in the current intrathecal therapy environment: an online survey. , 2009, Pain medicine.

[75]  J. Douketis,et al.  Perioperative anticoagulation in patients having implantation of a cardiac pacemaker or defibrillator: a systematic review and practical management guide , 2008, Journal of thrombosis and haemostasis : JTH.

[76]  Toshiyasu Suzuki,et al.  Spinal epidural hematoma following epidural catheter removal during antiplatelet therapy with cilostazol , 2008, Journal of Anesthesia.

[77]  P. Staats,et al.  Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain. , 2008, Pain medicine.

[78]  P. Felleiter,et al.  Device-related complications of long-term intrathecal drug therapy via implanted pumps , 2008, Spinal Cord.

[79]  M. Wallace,et al.  Intrathecal Ziconotide for Severe Chronic Pain: Safety and Tolerability Results of an Open-Label, Long-Term Trial , 2008, Anesthesia and analgesia.

[80]  C. Verheyen,et al.  The Safety and Efficacy of Extended Thromboprophylaxis With Fondaparinux After Major Orthopedic Surgery of the Lower Limb With or Without a Neuraxial or Deep Peripheral Nerve Catheter: The EXPERT Study , 2007, Anesthesia and analgesia.

[81]  S. Mercadante,et al.  Intrathecal Treatment in Cancer Patients Unresponsive to Multiple Trials of Systemic Opioids , 2007, The Clinical journal of pain.

[82]  S. Hassenbusch,et al.  Polyanalgesic Consensus Conference 2007: Recommendations for the Management of Pain by Intrathecal (Intraspinal) Drug Delivery: Report of an Interdisciplinary Expert Panel , 2007, Neuromodulation : journal of the International Neuromodulation Society.

[83]  Susan Smyth,et al.  Aspirin dose for the prevention of cardiovascular disease: a systematic review. , 2007, JAMA.

[84]  S. Butler,et al.  Psychiatric History and Psychologic Adjustment as Risk Factors for Aberrant Drug-related Behavior Among Patients With Chronic Pain , 2007, The Clinical journal of pain.

[85]  M. Dehghani,et al.  Does a Combination of Intensive Cognitive‐Behavioral Pain Management and a Spinal Implantable Device Confer any Advantage? A Preliminary Examination , 2006, Pain practice : the official journal of World Institute of Pain.

[86]  D. DeWalt,et al.  Predictors of opioid misuse in patients with chronic pain: a prospective cohort study , 2006, BMC Health Services Research.

[87]  A. L. Albright,et al.  Best-practice surgical techniques for intrathecal baclofen therapy. , 2006, Journal of neurosurgery.

[88]  M. Byas-Smith,et al.  Intrathecal Ziconotide in the Treatment of Chronic Nonmalignant Pain: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial , 2006, Neuromodulation : journal of the International Neuromodulation Society.

[89]  L. Webster,et al.  Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. , 2005, Pain medicine.

[90]  W. A. Katz,et al.  Section 3: The Nature of Pain: Pathophysiology , 2005, Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases.

[91]  J. Peragut,et al.  Intrathecal Morphine Infusion for Chronic Non‐Malignant Pain: A Multiple Center Retrospective Survey , 2004, Neuromodulation : journal of the International Neuromodulation Society.

[92]  R. Jamison,et al.  Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. , 2004, Journal of pain and symptom management.

[93]  S. Ozgoçmen,et al.  Spinal epidural hematoma associated with streptokinase treatment for myocardial infarction , 2004, Spinal Cord.

[94]  E. Kravitz,et al.  Intrathecal opioid treatment for chronic non-malignant pain: a 3-year prospective study , 2004, Pain.

[95]  L. Tonder,et al.  Intrathecal drug delivery for treatment of chronic low back pain: report from the National Outcomes Registry for Low Back Pain. , 2004, Pain medicine.

[96]  M. Byas-Smith,et al.  Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. , 2004, JAMA.

[97]  D. Sane,et al.  Risk of bleeding complications with antiplatelet agents: Meta‐analysis of 338,191 patients enrolled in 50 randomized controlled trials , 2004, American journal of hematology.

[98]  R. Rauck,et al.  Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain. , 2003, Journal of Pain.

[99]  Brian R. Phillips,et al.  Epidural, Cerebrospinal Fluid, and Plasma Pharmacokinetics of Epidural Opioids (Part 1): Differences among Opioids , 2003, Anesthesiology.

[100]  Brian R. Phillips,et al.  Epidural, Cerebrospinal Fluid, and Plasma Pharmacokinetics of Epidural Opioids (Part 2): Effect of Epinephrine , 2003, Anesthesiology.

[101]  M. Olsen,et al.  Risk factors for surgical site infection in spinal surgery. , 2003, Journal of neurosurgery.

[102]  T. Deer,et al.  Prevention of Intrathecal Drug Delivery Catheter‐Related Complications , 2003, Neuromodulation : journal of the International Neuromodulation Society.

[103]  G. Racz,et al.  Predictive Value of Intrathecal Narcotic Trials for Long‐Term Therapy with Implantable Drug Administration Systems in Chronic Non‐Cancer Pain Patients , 2002, Pain practice : the official journal of World Institute of Pain.

[104]  D. Schroeder,et al.  Risk Assessment of Hemorrhagic Complications Associated with Nonsteroidal Antiinflammatory Medications in Ambulatory Pain Clinic Patients Undergoing Epidural Steroid Injection , 2002, Anesthesia and analgesia.

[105]  Thomas J. Smith,et al.  Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[106]  Y. E. Mironer,et al.  Efficacy and Safety of Intrathecal Opioid/Bupivacaine Mixture in Chronic Nonmalignant Pain: A Double Blind, Randomized, Crossover, Multicenter Study by the National Forum of Independent Pain Clinicians (NFIPC) , 2002, Neuromodulation : journal of the International Neuromodulation Society.

[107]  Krishna Kumar,et al.  Treatment of chronic pain by using intrathecal drug therapy compared with conventional pain therapies: a cost-effectiveness analysis. , 2002, Journal of neurosurgery.

[108]  D. Caraway,et al.  Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine. , 2002, The spine journal : official journal of the North American Spine Society.

[109]  S. Hassenbusch,et al.  Intrathecal clonidine in the treatment of intractable pain: a phase I/II study. , 2002, Pain medicine.

[110]  L. J. Roberts,et al.  Outcome of intrathecal opioids in chronic non‐cancer pain , 2001, European journal of pain.

[111]  N. Rainov,et al.  Long-term intrathecal infusion of drug combinations for chronic back and leg pain. , 2001, Journal of pain and symptom management.

[112]  M. Kelly,et al.  Continuous intrathecal morphine treatment for chronic pain of nonmalignant etiology: long-term benefits and efficacy. , 2001, Surgical neurology.

[113]  A. Matsuki,et al.  Intrathecal methylprednisolone for intractable postherpetic neuralgia. , 2000, The New England journal of medicine.

[114]  K. Follett,et al.  A prospective study of catheter-related complications of intrathecal drug delivery systems. , 2000, Journal of pain and symptom management.

[115]  P. Isakson,et al.  Effects of Celecoxib, a Novel Cyclooxygenase‐2 Inhibitor, on Platelet Function in Healthy Adults: A Randomized, Controlled Trial , 2000, Journal of clinical pharmacology.

[116]  F. D. de Abajo,et al.  Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: population based case-control study , 1999, BMJ.

[117]  A. Matsuki,et al.  Comparative Therapeutic Evaluation of Intrathecal Versus Epidural Methylprednisolone for Long-term Analgesia in Patients With Intractable Postherpetic Neuralgia , 1999, Regional Anesthesia & Pain Medicine.

[118]  K J Burchiel,et al.  A prospective study of long-term intrathecal morphine in the management of chronic nonmalignant pain. , 1999, Neurosurgery.

[119]  R. Rosenquist,et al.  Neuraxial bleeding: fibrinolytics/thrombolytics. , 1998, Regional anesthesia and pain medicine.

[120]  W. Winkelmüller,et al.  Long-term effects of continuous intrathecal opioid treatment in chronic pain of nonmalignant etiology. , 1996, Journal of neurosurgery.

[121]  E. Connolly,et al.  Management of Spinal Epidural Hematoma After Tissue Plasminogen Activator: A Case Report , 1996, Spine.

[122]  Nathaniel Katz,et al.  Chronic opioid therapy for nonmalignant pain in patients with a history of substance abuse: report of 20 cases. , 1996, Journal of pain and symptom management.

[123]  S. Hassenbusch,et al.  Long-term intraspinal infusions of opioids in the treatment of neuropathic pain. , 1995, Journal of pain and symptom management.

[124]  T. Doubell,et al.  The pathophysiology of chronic pain — increased sensitivity to low threshold Aβ-fibre inputs , 1994, Current Opinion in Neurobiology.

[125]  I. Curelaru,et al.  Long‐term Intrathecal Morphine and Bupivacaine in Patients with Refractory Cancer Pain Results from a Morphine, Bupivacaine Dose Regimen of 0.5:4.75 mg/ml , 1994, Anesthesiology.

[126]  S. Morley,et al.  Intrathecal midazolam for the treatment of chronic mechanical low back pain: a controlled comparison with epidural steroid in a pilot study , 1992, Pain.

[127]  B. Condon,et al.  Changes in intracranial CSF volume after lumbar puncture and their relationship to post-LP headache. , 1991, Journal of neurology, neurosurgery, and psychiatry.

[128]  S. Einarsson,et al.  Long‐term intrathecal morphine and bupivacaine in “refractory” cancer pain. I. Results from the first series of 52 patients , 1991, Acta anaesthesiologica Scandinavica.

[129]  S. Vandenberg,et al.  Fluoxetine and the bleeding time. , 1990, Archives of pathology & laboratory medicine.

[130]  T. Yaksh,et al.  Long-term pain relief produced by intrathecal morphine infusion in 53 patients. , 1990, Journal of neurosurgery.

[131]  R. Penn,et al.  Chronic intrathecal morphine for intractable pain. , 1987, Journal of neurosurgery.

[132]  K. C. Srivastava Evidence for the mechanism by which garlic inhibits platelet aggregation. , 1986, Prostaglandins, leukotrienes, and medicine.

[133]  R. Urman,et al.  Responsible, Safe, and Effective Use of Antithrombotics and Anticoagulants in Patients Undergoing Interventional Techniques: American Society of Interventional Pain Physicians (ASIPP) Guidelines. , 2019, Pain physician.

[134]  Chong H. Kim Intrathecal Device Considerations , 2019, Deer's Treatment of Pain.

[135]  J. Pope Intrathecal Drug Delivery: Available Technologies , 2017 .

[136]  D. Koyyalagunta,et al.  Lumbar subarachnoid hematoma following an epidural blood patch for meningeal puncture headache related to the implantation of an intrathecal drug delivery system. , 2014, Pain physician.

[137]  J. Heavner,et al.  Ziconotide: an update and review. , 2008, Expert opinion on pharmacotherapy.

[138]  K. Sherman,et al.  Pathophysiological model for chronic low back pain integrating connective tissue and nervous system mechanisms. , 2007, Medical hypotheses.